Gen9

About:

Gen9 provides gene synthesis technology that enables the high-throughput, automated production of DNA constructs.

Website: http://www.gen9bio.com

Twitter/X: Gen9Bio

Top Investors: Agilent Technologies

Description:

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 was established in 2009 and is based in Cambridge, Massachusetts, United States.

Total Funding Amount:

$50.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)gen9bio.com

Founders:

Drew Endy, George Church, Joseph Jacobson

Number of Employees:

11-50

Last Funding Date:

2014-07-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai